Compound Discovered in Florida Keys Shows Potential as Colon Cancer Treatment
By LabMedica International staff writers Posted on 01 Nov 2010 |
A chemical compound made from a type of bacteria discovered in the Florida Keys (USA) by a pharmacy researcher has shown effectiveness in fighting colon cancer in preclinical research.
Writing online October 2010 in the Journal of Pharmacology and Experimental Therapeutics, scientists from the University of Florida (UF; Gainesville, USA) reported that the compound--known as largazole because it was first discovered near Key Largo--suppresses human cancer cell growth in cultures and rodent models by attacking a class of enzymes involved in the packaging and structure of DNA.
More research is needed, but scientists hope that the finding will lead to new treatments for the about 50,000 people struck with colorectal cancer each year in the United States. Researchers are enthusiastic because in addition to having the marine bacteria as a natural source of the chemical, they have been able to produce synthetically the active chemical compound extracted from the bacteria.
"It is challenging to develop natural marine products into drug therapies due to what is termed the ‘the supply problem,'” said Dr. Hendrik Luesch, an associate professor of medicinal chemistry in the UF College of Pharmacy. "We have solved the supply problem for largazole because it has a relatively simple structure, which has made it easy to reproduce in the lab.”
The Luesch lab discovered largazole while studying samples of bacteria from the Florida Keys, publishing the finding in 2008. Known as cyanobacteria, the microbes have evolved to fend off predators or deal with harsh conditions in a marine environment, employing toxins to aid their own survival. The toxins are the compounds chemists such as Dr. Luesch desire to isolate and understand in a quest to create drugs that similarly fend off invading cancers in the body.
Since the discovery, Dr. Luesch's lab determined the compound inhibits enzymes known as histone deacetylases (HDACs), which are linked to many diseases and are increasingly viewed as promising for cancer therapy. Dr. Jiyong Hong, an assistant professor of chemistry at Duke University (Durham, NC, USA), teamed with the UF researchers to chemically reproduce the compound for additional preclinical testing, which indicates it is a potent inhibitor of cancer cells that has the right characteristics to reach its intended target without the toxic side effects of many cancer drugs.
"Knowing HDAC is the target that makes largazole effective means we can predict good drug properties because there are already two anticancer products on the market that work this way,” said Dr. Luesch, who is a member of the UF Shands Cancer Center.
Three important features make this marine compound more promising than other natural products as an effective cancer-fighting drug, Dr. Luesch noted that availability of supply, knowing its mode of action, and the fact that its cellular target is already a known anticancer target known to result in the necessary selectivity for cancer cells over normal cells.
Dr. Luesch presented the study's findings September 9, 2010, at the Marine Drug Discovery Symposium in Pohang, South Korea, and later in Mid-October at the Marine Natural Products Symposium in Phuket, Thailand. The research is planned for publication in the November 2010 issue of the Journal of Pharmacology and Experimental Therapeutics.
Related Links:
University of Florida
Duke University
Writing online October 2010 in the Journal of Pharmacology and Experimental Therapeutics, scientists from the University of Florida (UF; Gainesville, USA) reported that the compound--known as largazole because it was first discovered near Key Largo--suppresses human cancer cell growth in cultures and rodent models by attacking a class of enzymes involved in the packaging and structure of DNA.
More research is needed, but scientists hope that the finding will lead to new treatments for the about 50,000 people struck with colorectal cancer each year in the United States. Researchers are enthusiastic because in addition to having the marine bacteria as a natural source of the chemical, they have been able to produce synthetically the active chemical compound extracted from the bacteria.
"It is challenging to develop natural marine products into drug therapies due to what is termed the ‘the supply problem,'” said Dr. Hendrik Luesch, an associate professor of medicinal chemistry in the UF College of Pharmacy. "We have solved the supply problem for largazole because it has a relatively simple structure, which has made it easy to reproduce in the lab.”
The Luesch lab discovered largazole while studying samples of bacteria from the Florida Keys, publishing the finding in 2008. Known as cyanobacteria, the microbes have evolved to fend off predators or deal with harsh conditions in a marine environment, employing toxins to aid their own survival. The toxins are the compounds chemists such as Dr. Luesch desire to isolate and understand in a quest to create drugs that similarly fend off invading cancers in the body.
Since the discovery, Dr. Luesch's lab determined the compound inhibits enzymes known as histone deacetylases (HDACs), which are linked to many diseases and are increasingly viewed as promising for cancer therapy. Dr. Jiyong Hong, an assistant professor of chemistry at Duke University (Durham, NC, USA), teamed with the UF researchers to chemically reproduce the compound for additional preclinical testing, which indicates it is a potent inhibitor of cancer cells that has the right characteristics to reach its intended target without the toxic side effects of many cancer drugs.
"Knowing HDAC is the target that makes largazole effective means we can predict good drug properties because there are already two anticancer products on the market that work this way,” said Dr. Luesch, who is a member of the UF Shands Cancer Center.
Three important features make this marine compound more promising than other natural products as an effective cancer-fighting drug, Dr. Luesch noted that availability of supply, knowing its mode of action, and the fact that its cellular target is already a known anticancer target known to result in the necessary selectivity for cancer cells over normal cells.
Dr. Luesch presented the study's findings September 9, 2010, at the Marine Drug Discovery Symposium in Pohang, South Korea, and later in Mid-October at the Marine Natural Products Symposium in Phuket, Thailand. The research is planned for publication in the November 2010 issue of the Journal of Pharmacology and Experimental Therapeutics.
Related Links:
University of Florida
Duke University
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
A new clinical chemistry analyzer is designed to provide outstanding performance and maximum efficiency, without compromising affordability, to meet the growing demands of modern laboratories.... Read more
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read moreMolecular Diagnostics
view channel
Blood-Based Biomarkers Could Detect Alzheimer's as Early as Middle Age
As the global population ages, Alzheimer's disease and other dementing diseases are becoming more prevalent. The disease processes leading to Alzheimer's symptoms can begin years or even decades before... Read more
RNA Screening Test Could Detect Colon Polyps Before They Become Cancerous
Colorectal cancer has become a growing health crisis, especially as it increasingly affects younger adults in their 20s, 30s, and 40s, while screening rates remain low. Colorectal cancer is now the leading... Read more
New RT-LAMP Assay Offers Affordable and Reliable Pathogen Detection for Resource-Limited Settings
The high cost and logistical complexities associated with rapid, point-of-care tests have long hampered widespread access to molecular diagnostics, especially in low- and middle-income countries.... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreImmunology
view channel
Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer
Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more
Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes
Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read moreMicrobiology
view channel
Viral Load Tests Can Help Predict Mpox Severity
Mpox is a viral infection that causes flu-like symptoms and a characteristic rash, which evolves significantly over time and varies between patients. The disease spreads mainly through direct contact with... Read more
Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
Gestational diabetes mellitus is a common metabolic disorder marked by abnormal glucose metabolism during pregnancy, typically emerging in the mid to late stages. It significantly heightens the risk of... Read morePathology
view channel
Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels
Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more
New AI-Based Method Effectively Identifies Disease Phenotypes Using Light-Based Imaging
Precision medicine, where treatment strategies are tailored to a patient's unique disease characteristics, holds great promise for cancer therapy. However, identifying disease phenotypes, which are critical... Read more
AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care
Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read moreTechnology
view channel
Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation
Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Ultra-Sensitive Biosensor Based on Light and AI Enables Early Cancer Diagnosis
Cancer diagnosis is often delayed due to the difficulty in detecting early-stage cancer markers. In particular, the concentration of methylated DNA in the bloodstream during the early stages of cancer... Read moreIndustry
view channel
BD Biosciences & Diagnostic Solutions to Merge with Waters
BD (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) and Waters Corporation (Milford, MA, USA) have entered into a definitive agreement to combine BD's Biosciences & Diagnostic Solutions... Read more